1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:39 2022-08-05 am EDT
53.10 EUR   +2.95%
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galapagos NV Announces Executive Appointments

04/26/2022 | 04:01pm EDT

Galapagos NV announces that the proposed resolutions presented at the extraordinary and annual shareholders’ meetings were approved, including the implementation of a one-tier governance structure. Subsequently, the newly installed board appointed Dr. Paul Stoffels as chairman of the board. The AGM approved, amongst other items, the appointment of Dr. Paul Stoffels as director, and of Jérôme Contamine and Dr. Dan Baker as independent directors.


© S&P Capital IQ 2022
All news about GALAPAGOS NV
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
08/04Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/15Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
06/22TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
06/22Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
MT
06/21Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
MT
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 557 M 566 M 566 M
Net income 2022 -143 M -145 M -145 M
Net cash 2022 3 478 M 3 533 M 3 533 M
P/E ratio 2022 -26,5x
Yield 2022 -
Capitalization 3 490 M 3 545 M 3 545 M
EV / Sales 2022 0,02x
EV / Sales 2023 0,57x
Nbr of Employees 1 305
Free-Float 73,7%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 53,10 €
Average target price 60,56 €
Spread / Average Target 14,0%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV7.88%3 545
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235